NewAmsterdam Pharma received European Commission approval for its drug obicetrapib, marking the first regulatory approval worldwide. The company also started a Phase 2b trial for obicetrapib in preclinical Alzheimer’s disease and expects interim results from its cardiovascular PREVAIL trial by early 2027. With $643 million in cash, NewAmsterdam is progressing multiple Phase 3 trials targeting cardiovascular disease, addressing unmet needs in LDL cholesterol management and expanding into neurodegenerative disease research.
NewAmsterdam Pharma's corporate update and Q3 financial results provide context for health-sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 18:41 WIB: out of 150 priced US health-sector stocks, 118 rose and 24 fell. Notable movers include TLRY at USD 2.81 (+6.04%, 96% Sell / 4% Buy), INO at USD 1.76 (+6.02%, 53% Sell / 47% Buy), and HRTX at USD 0.30 (+5.37%, 34% Sell / 66% Buy).
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
Dimensional Fund Advisors Ltd. has disclosed an interest in 1,516,595 ordinary shares of DCC Energy plc, representing 1.78% of the company's shares as of November 3, 2026. The disclosure follows regulatory requirements under the Irish Takeover Panel ...
reUSD is now available on the Monad blockchain, allowing users to access tokenized reinsurance yields beyond Ethereum. Users can bridge reUSD from Ethereum to Monad via Chainlink CCIP and engage with markets on Morpho and Pendle. On Monad, users can ...
